MOST FUNDED STARTUPS

Intarcia Therapeutics , Inc . develops treatments to optimize therapeutic benefits and reduce adverse effects for chronic and life-threatening diseases . The company also focuses on evaluating a series of human peptides for the treatment of obesity through its technology platform . Intarcia ’ s lead product candidate , ITCA 650 ( continuous subcutaneous delivery of

exenatide ), is currently in phase 3 development for the treatment of type 2 diabetes . Three phase 3 studies have been successfully completed , and one is ongoing . Intarcia expects to file for regulatory approval of ITCA 650 in the U . S . in 2016 . Intarcia Therapeutics has a strategic partnership with Quintiles , Inc . and Servier . The company was formerly known as BioMedicines , Inc . and changed its name to Intarcia Therapeutics , Inc . in September 2004 . The company was incorporated in 1995 and is headquartered in Boston , Massachusetts .

29